The combination treatments of BRAF inhibitors (vemurafenib) and EGFR inhibitors, namely gefitinib, erlotinib, or cetuximab, in patients with CRC synergistically inhibited mutated BRAF V600E (BRAFV600E) tumor growth in xenograft models [141]. This evidence concerns the gene BRAF and neoplasm.